Česky English
532 23 1111

Sedmý rámcový program


PanCare Studies in Fertility and Ototoxicity to Improve Quality of Life after Cancer during Childhood, Adolescence and Young Adulthood



PROJECT NO: 602030

DURATION: 1.11.2013 - 31.10.2018

COORDINATOR:Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz



Centre Hospitalier Universitaire Saint Etienne - Chu

Stichting Vu-Vumc

Fakultni nemocnice v Motole

Fakultni nemocnice Brno – MUDr. Tomáš Kepák

Boyne Research Institute Limited

Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz

Pintail Ltd

Academisch Medisch Centrum Bij De Universiteit Van Amsterdam

Istituto Giannina Gaslini

Kraeftens Bekaempelse

Westfaelische Wilhelms-Universitaet Muenster

Universitaetsklinikum Erlangen

Universitaet Bern

Erasmus Universitair Medisch Centrum Rotterdam

Charite - Universitaetsmedizin Berlin



Survival rates after childhood cancer now reach nearly 80% in developed European countries as a result of more effective therapies and better supportive care, leading to a steady increase in the number of survivors in the population. However, the treatments that have improved survival are harsh and cause serious side-effects that can greatly impact survivors’ quality of life in the long term. The goal of PanCareLIFE is that survivors of cancer diagnosed before age 25 should enjoy the same quality of life and opportunities as their peers who have not had cancer. Using observational studies and molecular genetic investigations PanCareLIFE will investigate late effects that impact fertility and hearing impairment (ototoxicity), and will assess health-related quality of life. Information from PanCareLIFE’s studies will be incorporated into new guidelines for fertility preservation. As the number of survivors with late effects in any one country is small, large cohorts are required for accurate estimation of risk. PanCareLIFE has assembled a team of prominent investigators from 8 European countries who will contribute in total over 12,000 well-characterised research subjects to identify risk factors, both genetic and non-genetic, linked to decrements in fertility and ototoxicity. Quality-of-life studies will evaluate the impact of fertility and ototoxicity. PanCareLIFE will advance the state-of-the-art in survivorship studies by evaluation of large cohorts with observational and genetic tools that will provide better knowledge of individual risk factors. Survivors can then be stratified into groups benefitting from personalized, evidence-based, care; future patients may expect effective therapies to have less severe side effects, and plans for a seamless transition to long-term follow-up care can be made. These approaches will result in better quality of life for survivors of cancer diagnosed at a young age.

The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells(BM-MNC) on All Cause Mortality in Acute Myocardial Infarction



PROJECT NO: 278967

DURATION: 1.11.2011 - 31.10.2016

COORDINATOR:  Professor Anthony Mathur, Queen Mary and Westfield College, University of London



Queen Mary and Westfield College, University of London (Prof Anthony Mathur, Co-ordinator)

Assistance Publique – Hopitaux de Paris

Katholieke Universiteit Leuven

Johann Wolfgang Goethe-Universitat in Frankfurt

Institut Catala de la Salut

EURAM Limited

University College London

t2cure GmbH

Cardiovascular Research Center VZW

Medizinische Hochschule Hannover

University Hospital Brno - MUDr. Petr Kala, Ph.D.


Universita Cattolica del Sacro Cuore

King’s College Hospital

Śląski Uniwersytet Medyczny w Katowicach

Universitaet Rostock

Cardio3 BioSciences S.A. (Dr Atta Behfar, Exploitation Manager)

Itä-Suomen yliopisto

Oslo Universitetssykehus HF

Hospital General Universitario Gregorio Maranón

The University of Exeter



Although the long term prognosis of patients suffering acute myocardial infarction (AMI) has improved since the introduction of reperfusion therapies and primary angioplasty, the 1 year mortality of patients with AMI and resultant left ventricular systolic dysfunction (LVSD) is still as high as 13%. A major reason for the high morbidity and mortality is that the heart has an inadequate regenerative response to the myocardial necrosis sustained following AMI; cell death from the ischaemic damage can lead to progressive ventricular dilation and dysfunction through the processes of vascular remodelling. Despite the use of full conventional treatment, including ACE inhibitors, beta-blockers, aldosterone inhibitors and diuretics, yearly mortality rates of patients with post-infarction heart failure are still in the range of 13 % and rehospitalisation for worsening of heart failure occurs at a yearly rate of 6–8%. Clinical data now exists supporting the concept that autologous bone marrow derived cells can restore cardiac function following AMI. We plan to advance this research in the BAMI project and will: • Develop a standardised method of bone marrow cell collection • Develop a standardised method of optimising reparative potential of bone marrow derived cells • Standardise bone marrow preparation procedure so that it can be universally applied • Standardise method of bone marrow cell delivery post AMI • Conduct the first large scale all course mortality clinical trial to test if the product and delivery method mentioned above can lead to a 25% reduction in mortality end-point at 2 years Our project will establish the therapeutic value of this approach to stem cell therapy. Success will demonstrate that transcoronary infusion of bone marrow-derived progenitor cells is safe and will reduce the mortality rate by 25% and reduce the rehospitalisation rate by 15%.

Informace o pohotovosti v Brně a Jihomoravském kraji